As of 2024-07-27, the EV/EBITDA ratio of Heron Therapeutics Inc (HRTX) is -7.54. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HRTX's latest enterprise value is 588.57 mil USD. HRTX's TTM EBITDA according to its financial statements is -78.11 mil USD. Dividing these 2 quantities gives us the above HRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 23.3x | 20.5x |
| Forward P/E multiples | 21.8x - 25.1x | 24.2x |
| Fair Price | (12.17) - (12.95) | (12.43) |
| Upside | -499.0% - -524.5% | -507.6% |
| Date | EV/EBITDA |
| 2024-07-26 | -7.54 |
| 2024-07-25 | -7.63 |
| 2024-07-24 | -7.73 |
| 2024-07-23 | -7.77 |
| 2024-07-22 | -7.82 |
| 2024-07-19 | -7.92 |
| 2024-07-18 | -8.08 |
| 2024-07-17 | -8.40 |
| 2024-07-16 | -8.73 |
| 2024-07-15 | -8.04 |
| 2024-07-12 | -7.90 |
| 2024-07-11 | -8.04 |
| 2024-07-10 | -7.52 |
| 2024-07-09 | -7.31 |
| 2024-07-08 | -7.38 |
| 2024-07-05 | -7.19 |
| 2024-07-03 | -7.00 |
| 2024-07-02 | -6.94 |
| 2024-07-01 | -8.35 |
| 2024-06-28 | -8.40 |
| 2024-06-27 | -8.23 |
| 2024-06-26 | -8.08 |
| 2024-06-25 | -7.54 |
| 2024-06-24 | -7.79 |
| 2024-06-21 | -7.88 |
| 2024-06-20 | -8.00 |
| 2024-06-18 | -8.25 |
| 2024-06-17 | -7.87 |
| 2024-06-14 | -8.60 |
| 2024-06-13 | -8.66 |
| 2024-06-12 | -8.71 |
| 2024-06-11 | -8.67 |
| 2024-06-10 | -8.77 |
| 2024-06-07 | -8.60 |
| 2024-06-06 | -8.65 |
| 2024-06-05 | -9.02 |
| 2024-06-04 | -8.60 |
| 2024-06-03 | -9.10 |
| 2024-05-31 | -8.79 |
| 2024-05-30 | -8.31 |
| 2024-05-29 | -7.96 |
| 2024-05-28 | -8.23 |
| 2024-05-24 | -8.29 |
| 2024-05-23 | -8.35 |
| 2024-05-22 | -8.35 |
| 2024-05-21 | -8.29 |
| 2024-05-20 | -8.21 |
| 2024-05-17 | -7.82 |
| 2024-05-16 | -7.86 |
| 2024-05-15 | -7.44 |